Estrella Immunopharma, Inc.
ESLANASDAQHealthcare● Active
$1.13
$-0.01(-0.88%)
Market Cap$48628646
P/E Ratio—
52W High$3.15
52W Low$0.78
Estrella Immunopharma, Inc. (ESLA) Earnings: Dates, EPS & Revenue History
Quarterly EPS vs. estimates, revenue surprises, next earnings date, and analyst consensus.
ESLA · earnings · updated Jun 8, 2026
Latest Earnings
Q2 FY2026Report Date: May 15, 2026EPS Actual
-$0.05
Est. -$0.08 · +40.5%
Revenue
—
Fiscal Period
Q2 FY2026
FY ends December
Report Date
May 15, 2026
After Market Close
▲ Beat EPS✓ 3-Quarter EPS Beat Streak
ESLA reports quarterly as a NASDAQ-listed Biotechnology company. Fiscal year ends in December. Data: FMP · Updated hourly.
Next Earnings Date
Days Away
85
days
Expected Date
Sep 1, 2026
Fiscal Period
Q3 FY2026
Release Time
◌ Time TBD (Unconfirmed)EPS Est.
$0.09
Rev. $41.31B
Days Away85
Expected DateSep 1, 2026
Fiscal PeriodQ3 FY2026
Release TimeTime TBD (Unconfirmed)
EPS Est.$0.09
Rev. Est.$41.31B
EPS & Revenue vs. Estimates
Actual (Beat)
Actual (Miss)
Estimated
Earnings History
| Period | Report Date | EPS Est. | EPS Actual | EPS Surpr. | Revenue | Rev. Est. | Rev. Surpr. |
|---|---|---|---|---|---|---|---|
| ◌ Q3 FY2026 | Sep 2, 2026 | -$0.08 | — | — | — | — | — |
| ▲ Q2 FY2026 | May 15, 2026 | -$0.08 | -$0.05 | +40.5% | — | — | — |
| ▲ Q1 FY2026 | Mar 18, 2026 | -$0.18 | -$0.02 | +91.0% | — | — | — |
| ▲ Q4 FY2025 | Nov 12, 2025 | -$0.19 | -$0.13 | +30.3% | — | — | — |
| ▼ Q3 FY2025 | Aug 11, 2025 | -$0.07 | -$0.15 | -114.3% | — | — | — |
| ▲ Q2 FY2025 | May 14, 2025 | -$0.11 | -$0.06 | +45.5% | — | — | — |
| ▲ Q1 FY2025 | Feb 15, 2025 | -$0.12 | -$0.03 | +76.1% | — | — | — |
| — Q4 FY2024 | Nov 14, 2024 | — | -$0.09 | — | — | — | — |
Q3 FY2026
Sep 2, 2026
EPS Actual
—
EPS Est.
-$0.08
EPS Surpr.
—
Revenue
—
Q2 FY2026
May 15, 2026Beat
EPS Actual
-$0.05
EPS Est.
-$0.08
EPS Surpr.
+40.5%
Revenue
—
Q1 FY2026
Mar 18, 2026Beat
EPS Actual
-$0.02
EPS Est.
-$0.18
EPS Surpr.
+91.0%
Revenue
—
Q4 FY2025
Nov 12, 2025Beat
EPS Actual
-$0.13
EPS Est.
-$0.19
EPS Surpr.
+30.3%
Revenue
—
Q3 FY2025
Aug 11, 2025Miss
EPS Actual
-$0.15
EPS Est.
-$0.07
EPS Surpr.
-114.3%
Revenue
—
Q2 FY2025
May 14, 2025Beat
EPS Actual
-$0.06
EPS Est.
-$0.11
EPS Surpr.
+45.5%
Revenue
—
Q1 FY2025
Feb 15, 2025Beat
EPS Actual
-$0.03
EPS Est.
-$0.12
EPS Surpr.
+76.1%
Revenue
—
Q4 FY2024
Nov 14, 2024
EPS Actual
-$0.09
EPS Est.
—
EPS Surpr.
—
Revenue
—
Analyst Estimates
Limited analyst coverage (fewer than 3 analysts). Estimates may not reflect market consensus.
EPS Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q2 FY2028 | $-0.02 | $-0.02 | $-0.02 | 1 |
| Q1 FY2028 | $-0.03 | $-0.03 | $-0.03 | 1 |
| Q4 FY2027 | $-0.04 | $-0.04 | $-0.04 | 1 |
| Q3 FY2027 | $-0.05 | $-0.05 | $-0.05 | 1 |
| Q2 FY2027 | $-0.11 | $-0.11 | $-0.11 | 1 |
| Q1 FY2027 | $-0.12 | $-0.12 | $-0.12 | 1 |
Revenue Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q2 FY2028 | $0.0B | $0.0B | $0.0B | 1 |
| Q1 FY2028 | $0.0B | $0.0B | $0.0B | 1 |
| Q4 FY2027 | $0.0B | $0.0B | $0.0B | 1 |
| Q3 FY2027 | $0.0B | $0.0B | $0.0B | 1 |
| Q2 FY2027 | $0.0B | $0.0B | $0.0B | 0 |
| Q1 FY2027 | $0.0B | $0.0B | $0.0B | 0 |
Earnings Price Reaction
Closing price one trading day before vs. one trading day after each earnings release.
| Period | Report Date | EPS Beat/Miss | Price Before | Price After | 1D Reaction |
|---|---|---|---|---|---|
| ▲ Q2 FY2026 | May 15, 2026 | +40.5% | $1.21 | $1.11 | -8.26% |
| ▲ Q1 FY2026 | Mar 18, 2026 | +91.0% | $1.11 | $1.08 | -2.70% |
| ▲ Q4 FY2025 | Nov 12, 2025 | +30.3% | $2.51 | $2.10 | -16.33% |
| ▼ Q3 FY2025 | Aug 11, 2025 | -114.3% | $0.82 | $0.87 | +5.10% |
| ▲ Q2 FY2025 | May 14, 2025 | +45.5% | $1.03 | $0.99 | -3.88% |
| ▲ Q1 FY2025 | Feb 15, 2025 | +76.1% | $1.24 | $1.44 | +16.13% |
| — Q4 FY2024 | Nov 14, 2024 | — | $0.84 | $0.84 | +0.00% |
| — Q3 FY2024 | Sep 27, 2024 | — | $0.97 | $1.19 | +22.69% |
Q2 FY2026-8.26%
Report Date
May 15, 2026
EPS Beat/Miss
+40.5%
Price Before
$1.21
Price After
$1.11
Q1 FY2026-2.70%
Report Date
Mar 18, 2026
EPS Beat/Miss
+91.0%
Price Before
$1.11
Price After
$1.08
Q4 FY2025-16.33%
Report Date
Nov 12, 2025
EPS Beat/Miss
+30.3%
Price Before
$2.51
Price After
$2.10
Q3 FY2025+5.10%
Report Date
Aug 11, 2025
EPS Beat/Miss
-114.3%
Price Before
$0.82
Price After
$0.87
Q2 FY2025-3.88%
Report Date
May 14, 2025
EPS Beat/Miss
+45.5%
Price Before
$1.03
Price After
$0.99
Q1 FY2025+16.13%
Report Date
Feb 15, 2025
EPS Beat/Miss
+76.1%
Price Before
$1.24
Price After
$1.44
Q4 FY2024+0.00%
Report Date
Nov 14, 2024
EPS Beat/Miss
—
Price Before
$0.84
Price After
$0.84
Q3 FY2024+22.69%
Report Date
Sep 27, 2024
EPS Beat/Miss
—
Price Before
$0.97
Price After
$1.19
Avg Beat Reaction-3.01%
Avg Miss Reaction+5.10%
Beat Rate5 / 8 quarters
Largest Move+22.69% (Q3 FY2024)
Data: FMP /historical-price-eod/full · field: close
About Earnings & Data Methodology
Data source: Financial Modeling Prep (FMP) | Updated: Hourly | Surprise%: (Actual − Estimate) / |Estimate| × 100 | Fiscal year: ESLA ends December
Estrella Immunopharma, Inc. (ESLA) most recently reported earnings on May 15, 2026 for Q2 FY2026, posting EPS of $-0.05 — beating the analyst consensus of $-0.08 by +40.5%. ESLA has beaten EPS estimates for 3 consecutive quarters. The next ESLA earnings date is expected around September 1, 2026.
Each quarter, investors track ESLA earnings for signals on forward guidance and business momentum. For longer-term revenue trends, see the Revenue tab. ESLA revenue tab →
Earnings Glossary
EPS (Earnings Per Share)
Net income ÷ diluted shares outstanding. The primary metric analysts use to gauge quarterly profitability.
Earnings Surprise %
(Actual − Estimate) / |Estimate| × 100. Positive = Beat. Negative = Miss.
Beat / Miss / In-Line
Beat = Actual ≥ Estimate. Miss = Actual < Estimate. In-Line = within ±1%.
BMO / AMC
Before Market Open / After Market Close. Two windows when companies typically release results.
Fiscal Quarter
ESLA's fiscal year ends in December. Fiscal quarters may not align with calendar quarters.
Analyst Consensus
Average EPS/Revenue forecast across all covering analysts. More analysts = more reliable estimate.
Figures tie to FMP earnings calendar, estimates, and SEC 10-Q/10-K filings where noted.
Frequently asked questions
ESLA earnings · 5 questionsEstrella Immunopharma, Inc.'s next earnings report is expected around September 1, 2026. ESLA typically reports quarterly — approximately every three months. The exact date is confirmed by the company 2–4 weeks before the release. Time is currently TBD; ESLA historically reports after market close (AMC).
ESLA earnings datewhen is ESLA earningsESLA next earnings datewhen does ESLA report earningsESLA earnings calendar
▸ Source: FMP · Estrella Immunopharma, Inc. SEC filings · US GAAP · Estrella Immunopharma, Inc. SEC 10-K & 10-Q filings · US GAAP · Updated: Jun 8, 2026